

DAFTAR PUSTAKA

- Angelia. (2021). Evaluasi Penggunaan Obat Antihipertensi pada Pasien Gagal Ginjal Kronis. Puskesmas Kolongan.
- Angelia. (2021). Evaluasi penggunaan obat antihipertensi pada pasien gagal ginjal kronik. Laporan Penelitian, Puskesmas Kolongan.
- Anna, dkk. (2020). Penggunaan Obat Antihipertensi pada Pasien GGK di RSUDP NTB. *Jurnal Farmasi Klinik Indonesia*, 12(3), 45–52.
- Aronoff, G. R., Bennett, W. M., Berns, J. S., Brier, M. E., Kasbekar, N., & Mueller, B. A. (2007). Drug prescribing in renal failure: Dosing guidelines for adults and children (5th ed.). American College of Physicians.
- Bakris, G. L., & Ritz, E. (2009). The role of the renin–angiotensin system in the progression of chronic kidney disease. *American Journal of Kidney Diseases*, 54(1), 16–26.
- Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., ... & Virani, S. S. (2019). Heart disease and stroke statistics—2019 update: A report from the American Heart Association. *Circulation*, 139(10), e56–e528.
- Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H. H., ... & Ruilope, L. M. (2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *The New England Journal of Medicine*, 345(12), 861–869.
- Brown, K., Patel, R., & Lee, S. (2019). Concurrent review of patient care: Impact on treatment outcomes. *Healthcare Quality Journal*, 8(2), 75–82.
- Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2018). Goodman & Gilman's: The pharmacological basis of therapeutics (13th ed.). McGraw-Hill Education.
- Carrero, J. J., & Anders, H. J. (2018). Sex differences in chronic kidney disease: Underlying mechanisms and implications for clinical practice. *Nature Reviews Nephrology*, 14(3), 151–164.
- Carretero, O. A., & Oparil, S. (2000). Essential hypertension: Part I: Definition and etiology. *Circulation*, 101(3), 329–335.
- Carver, J., Jamal, M., & Anderson, J. (2023). Clinical Drug Use Review: Standards and Approaches. *Journal of Rational Pharmacotherapy*, 29(1), 1–14.

- Chobanian, A. V., et al. (2003). The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension*, 42(6), 1206–1252.
- Chou, M. C., Lin, J. L., & Chen, H. C. (2012). Increased risk of chronic kidney disease among users of non-prescribed Chinese herbal medicine in Taiwan. *American Journal of Kidney Diseases*, 59(5), 729–735.
- Danaei, G., Finucane, M. M., Lin, J. K., et al. (2011). National, regional, and global trends in systolic blood pressure since 1980: Systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. *The Lancet*, 377(9765), 568–577.
- Ekantari, N. W. (2012). Penyakit ginjal polikistik: Tinjauan patofisiologi dan penatalaksanaannya. *Majalah Kedokteran Udayana*, 1(2), 35–41.
- Esi, N. (2019). Evaluasi Ketepatan Pemilihan Obat Antihipertensi di RSUD NTB. *Jurnal Farmasi*, 14(2), 34–41.
- Franklin, S. S., Gustin, W., Wong, N. D., Larson, M. G., Weber, M. A., Kannel, W. B., & Levy, D. (1997). Hemodynamic patterns of age-related changes in blood pressure: The Framingham Heart Study. *Circulation*, 96(1), 308–315.
- Green, D., & Taylor, P. (2021). Prospective assessment in clinical therapy planning. *International Journal of Medical Practice*, 12(1), 45–53.
- Guyton, A. C., & Hall, J. E. (2020). *Textbook of Medical Physiology* (14th ed.). Elsevier.
- Humphrey, J. D., Harrison, D. G., & Figueroa, C. A. (2016). Central artery stiffness in hypertension: Mechanisms and clinical relevance. *Circulation Research*, 118(3), 379–381.
- Intengan, H. D., & Schiffrin, E. L. (2001). Vascular remodeling in hypertension: Roles of apoptosis, inflammation, and fibrosis. *Hypertension*, 38(3), 581–587.
- James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., ... & Smith, S. C. (2014). 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*, 311(5), 507–520.
- Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., ... & Yang, C. W. (2024). Chronic kidney disease: Global dimension and perspectives. *The Lancet*, 405(10275), 261–272.
- Johnson, R. J., & Feehally, J. (2018). *Comprehensive Clinical Nephrology* (6th ed.). Elsevier.

- Johnson, R. J., Feehally, J., & Floege, J. (2012). *Comprehensive Clinical Nephrology* (4th ed.). Elsevier.
- Kang, H. M., Ahn, S. H., Choi, P., Ko, Y. A., Han, S. Y., Chinga, F., ... & Susztak, K. (2015). Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. *Nature Medicine*, 21(1), 37–46.
- Kannel, W. B., & Vasan, R. S. (2009). Hypertension in the elderly: Diagnosis and management. *Journal of Clinical Hypertension*, 11(4), 202–209.
- KDIGO. (2021). KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD. *Kidney International Supplements*, 11(3), 1–87.
- Kearney, P. M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P. K., & He, J. (2005). Global burden of hypertension: Analysis of worldwide data. *The Lancet*, 365(9455), 217–223.
- Kementerian Kesehatan Republik Indonesia. (2014). *Riset Kesehatan Dasar (Riskesdas)*. Jakarta: Badan Penelitian dan Pengembangan Kesehatan.
- Kementerian Kesehatan Republik Indonesia. (2021). *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Hipertensi Dewasa*. Jakarta: Kemenkes RI.
- Kementerian Kesehatan Republik Indonesia. (2023). *Pedoman Manajemen Gagal Ginjal Kronik di Fasilitas Kesehatan*. Jakarta: Kemenkes RI.
- Kidney Disease: Improving Global Outcomes (KDIGO). (2012). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney International Supplements*, 3(1), 1–150.
- Klag, M. J., Whelton, P. K., Randall, B. L., Neaton, J. D., Brancati, F. L., Ford, C. E., ... & Stamler, J. (1997). Blood pressure and end-stage renal disease in men. *The New England Journal of Medicine*, 334(1), 13–18.
- Ku, E., Lee, B. J., Wei, J., & Weir, M. R. (2019). Hypertension in CKD: Core curriculum 2019. *American Journal of Kidney Diseases*, 74(1), 120–131.
- Kumar, V., Abbas, A. K., & Aster, J. C. (2021). *Robbins Basic Pathology* (10th ed.). Elsevier.
- Lai, J. N., Hsieh, S. C., Chen, P. C., & Wang, J. D. (2007). Herbal therapy is associated with risk of chronic kidney disease in adults not using analgesics in Taiwan. *American Journal of Kidney Diseases*, 49(5), 626–633.
- Laurent, S., Boutouyrie, P., Cunha, P. G., Oliveira, I., Fortier, C., & Amar, L. (2016). Aortic stiffness and central blood pressure: Biomarkers of cardiovascular risk. *Hypertension*, 68(5), 1056–1059.

- Lestari, D. I., Prawito, N., & Rustanti, E. (2023). *Hubungan Pengetahuan Pasien Tentang Penyakit Gagal Ginjal Kronis dengan Kepatuhan Diet di Ruang Hemodialisis RSUD Lawang*. **Prima Wiyata Health**, 4(1), 16–29.
- Levin, A., Hemmelgarn, B., Culleton, B., Tobe, S., McFarlane, P., Ruzicka, M., ... & Manns, B. (2003). Guidelines for the management of chronic kidney disease. *Canadian Medical Association Journal*, 168(6), 1421–1433.
- Lewis, S. M., Dirksen, S. R., Heitkemper, M. M., & Bucher, L. (2013). *Medical-Surgical Nursing: Assessment and Management of Clinical Problems* (8th ed.). Mosby.
- Marieb, E. N., & Hoehn, K. (2018). *Human Anatomy & Physiology* (11th ed.). Pearson.
- Marrs, J. A., Hemmelgarn, B. R., Tonelli, M., & Manns, B. J. (2018). Albuminuria and kidney disease progression: A review of the clinical implications. *Nephrology Dialysis Transplantation*, 33(5), 769–775.
- Mills, K. T., Bundy, J. D., Kelly, T. N., Reed, J. E., Kearney, P. M., Reynolds, K., ... & He, J. (2016). Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. *Circulation*, 134(6), 441–450.
- Muntner, P., Whelton, P. K., Woodward, M., et al. (2019). Use of blood pressure lowering medications and cardiovascular risk. *Hypertension*, 73(5), 999–1006.
- Neugarten, J., & Golestaneh, L. (2019). Influence of sex on the progression of chronic kidney disease. *Mayo Clinic Proceedings*, 94(7), 1339–1356.
- Novycha, R. (2022). Penggunaan Obat Antihipertensi di RSUD Imelda Medan. *Jurnal Farmasi*, 10(1), 25–30.
- Oparil, S., Acelajado, M. C., Bakris, G. L., Berlowitz, D. R., Cífková, R., Dominiczak, A. F., ... & Weber, M. A. (2018). Hypertension. *Nature Reviews Disease Primers*, 4, 18014.
- Palmer, S. C., Hanson, C. S., Craig, J. C., Strippoli, G. F. M., & Tonelli, M. (2025). Hypertension in chronic kidney disease: New perspectives on management. *Journal of the American Society of Nephrology*, 36(2), 115–127.
- Pawlak, K., & Jaworski, J. (2014). Erythropoietin in chronic kidney disease. *International Journal of Nephrology and Renovascular Disease*, 7, 361–368.
- Pratama, A., Pertiwi, H., Setiyadi, A., & Pamungkas, I. G. (2025). *Kepatuhan Diet pada Pasien Penyakit Ginjal Kronis dalam Perspektif Pengetahuan Pasien dan Dukungan Keluarga: Studi Cross-Sectional*. **Promotif: Jurnal Kesehatan Masyarakat**, 13(2)

- Purba, F. D., et al. (2021). Prevalensi penyakit ginjal kronis di Indonesia berdasarkan data Riskesdas 2018. Jakarta: Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan RI.
- Puspitasari, R. (2023). Evaluasi penggunaan obat antihipertensi pada pasien gagal ginjal kronik di RSUD Dr. Soetomo. *Jurnal Ilmu Kefarmasian Indonesia*, 21(1), 55–62.
- Rahman, M., & DiBona, G. F. (2020). Sympathetic nervous system and blood pressure in chronic kidney disease. *Kidney International Reports*, 5(3), 231–240.
- Ramos-Casals, M., Brito-Zerón, P., López-Guillermo, A., Khamashta, M. A., & Bosch, X. (2018). Autoimmune diseases and kidney involvement: A comprehensive review. *Journal of Autoimmunity*, 93, 1–17.
- Remuzzi, G., & Bertani, T. (2002). Pathophysiology of progressive nephropathies. *The New England Journal of Medicine*, 346(20), 1396–1406.
- Renal Physiology. (2024). Understanding Kidney Function. Renal Health Resources.
- Rodriguez-Pena, A. A., Hake, P. W., & Rutkowski, J. M. (2011). Diabetes and renal disease: New insights and implications. *Clinical Nephrology*, 75(Suppl 1), S41–S51.
- Ruggenenti, P., Remuzzi, G., et al. (2022). The role of glomerular cells in kidney disease. *Nature Reviews Nephrology*, 18(3), 153–166.
- Sa'idah, S. (2019). Analisis Ketepatan Obat Hipertensi Berdasarkan JNC 8 di Puskesmas Kota Semarang. *Jurnal Ilmu Kesehatan*, 7(2), 89–95.
- Safar, M. E., & London, G. M. (2000). Arterial and venous compliance in sustained essential hypertension. *Hypertension*, 36(5), 895–900.
- Safar, M. E., Jankowski, P., & Boudier, H. A. J. (2018). Arterial stiffness, pulse pressure, and cardiovascular risk. *Pathologie Biologie*, 66(4), 241–245.
- Sari, R. N., & Putri, D. A. (2020). Evaluasi rasionalitas penggunaan obat antihipertensi pada pasien gagal ginjal kronik. *Jurnal Farmasi dan Klinis Indonesia*, 7(1), 22–28.
- Schena, F. P., & Gesualdo, L. (2005). Pathogenetic mechanisms of diabetic nephropathy. *Journal of the American Society of Nephrology*, 16(Supplement 1), S30–S33.

- Setiawan, H., Prasetya, R. E., & Nuraini, L. (2022). Pola penggunaan obat antihipertensi pada pasien gagal ginjal kronik di rumah sakit pendidikan. *Jurnal Ilmu Kefarmasian dan Kesehatan*, 9(2), 105–112.
- Shahbazian, H., & Rezaii, I. (2013). Diabetic kidney disease; review of the current knowledge. *Journal of Renal Injury Prevention*, 2(2), 73–80.
- Sharif, A., & Bagga, A. (2013). Epidemiology, clinical presentation, and outcome of congenital anomalies of the kidney and urinary tract in children. *Indian Journal of Pediatrics*, 80(5), 385–391.
- Sihatmasayu. (2010). *Anatomi dan Fisiologi Ginjal*. Bandung: Medika Press.
- Smith, D. H., Gullion, C. M., Nichols, G., Keith, D. S., & Brown, J. B. (2005). Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. *Journal of the American Society of Nephrology*, 15(5), 1300–1306.
- Smith, L., & Jones, M. (2020). Retrospective evaluation in healthcare: Methodologies and applications. *Journal of Clinical Evaluation*, 15(3), 123–130.
- Statearls. (2023). Prospective Drug Evaluation Standards in Clinical Settings. *Clinical Pharmacy Guidelines*, 22(2), 77–83.
- Subekti, D. (2024). *Hubungan Tingkat Pengetahuan Diet dengan Kepatuhan Diet pada Pasien Gagal Ginjal Kronik di Ruang Hemodialisa Rumah Sakit Husada Utama Surabaya*. **Pengembangan Ilmu dan Praktik Kesehatan**, 3(1), 40–51.
- Sumawa, N. M. (2015). Evaluasi penggunaan obat antihipertensi pada pasien gagal ginjal kronik rawat inap. *Jurnal Farmasi Udayana*, 4(3), 123–130.
- Sun, Z. (2014). Aging, arterial stiffness, and hypertension. *Hypertension*, 63(4), 446–449.
- Stenvinkel, P., Carrero, J. J., Axelsson, J., Lindholm, B., Heimbürger, O., & Massy, Z. A. (2015). Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle? *Clinical Journal of the American Society of Nephrology*, 10(3), 421–431.
- Suwitra, K. (2018). Peran hipertensi sebagai penyebab utama gagal ginjal kronik di Indonesia. *Acta Medica Indonesiana*, 50(3), 198–205.
- The Lancet. (2021). Chronic kidney disease and its global impact: A silent epidemic. *The Lancet*, 398(10302), 1231–1233.
- Thomas, R., Kanso, A., & Sedor, J. R. (2019). Chronic kidney disease and its complications. *Primary Care: Clinics in Office Practice*, 36(2), 329–344.

- Torres, V. E., Harris, P. C., & Pirson, Y. (2007). Autosomal dominant polycystic kidney disease. *The Lancet*, 369(9569), 1287–1301.
- Tortora, G. J., & Derrickson, B. (2018). *Principles of Anatomy and Physiology* (15th ed.). Wiley.
- Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., ... & Molitch, M. E. (2014). Diabetic kidney disease: A report from an ADA Consensus Conference. *Diabetes Care*, 37(10), 2864–2883.
- Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., ... & Molitch, M. E. (2014). Diabetic kidney disease: A report from an ADA Consensus Conference. *Diabetes Care*, 37(10), 2864–2883.
- Unnikrishnan, R., Anjana, R. M., Mohan, V., & Pradeepa, R. (2022). Burden and risk factors of chronic kidney disease in South Asia: A review. *Kidney International Reports*, 7(3), 456–465.
- Vaidya, G., & Aeddula, N. R. (2024). *Kidney Function and Disease Overview*. StatPearls Publishing.
- Vaidya, S. R., & Aeddula, N. R. (2025). *Chronic Kidney Disease*. In **StatPearls**. StatPearls Publishing. Retrieved from
- van den Bemt, B. J. F., Egberts, A. C. G., & de Jong-van den Berg, L. T. W. (2000). Quality indicators for drug use in hospitals: Development and practical implementation. *Journal of Clinical Pharmacy and Therapeutics*, 25(4), 299–305.
- Wada, J., & Makino, H. (2013). Inflammation and the pathogenesis of diabetic nephropathy. *Clinical Science*, 124(3), 139–152.
- Wahyuni, S., Putri, A. D., & Hidayat, R. (2018). Terapi pengganti ginjal pada pasien gagal ginjal kronik di rumah sakit Indonesia. *Jurnal Farmasi dan Ilmu Kefarmasian Indonesia*, 5(1), 45–52.
- Wang, Y., Niu, L., Wang, Y., Ma, Y., & Zheng, L. (2020). Prevalence, awareness, and control of chronic kidney disease in China: Results from a national survey. *BMC Nephrology*, 21, 301.
- Webster, A. C., Nagler, E. V., Morton, R. L., & Masson, P. (2020). Chronic kidney disease. *The Lancet*, 395(10225), 709–733.
- Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2017). 2017 ACC/AHA... Hypertension, 71(6), e13–e115.
- Whelton, P. K., et al. (2018). High blood pressure and cardiovascular disease. *Hypertension*, 71(1), 19–24.

- Yuliani, R., Mustika, N., & Hasanah, U. (2019). Efektivitas Bisoprolol pada Pasien GKG di RSUD Riau. *Jurnal Farmasi Klinik Indonesia*, 13(2), 74–81.
- Zhao, J., Li, H., Zhang, D., Yang, Y., Wang, J., & Lin, H. (2020). Hypertension and CKD: From epidemiology to clinical practice. *Kidney and Blood Pressure Research*, 45(2), 216–230.